For a change. Fool article suggests that it is because we have a blockbuster, whereas SGEN Acedris sales are merely incremental and pipeline a ways from any approvals.
Not to gloat, but...Every dog has its day in the sun, and we have been in the shadows long enough.
Even though the royalties are stingy, long awaited FDA approval will shine on IMGN and its powerful technology. The next deal won't come so cheap, and if we can sell our own drug, now that would really be a big deal, to politely paraphrase vice president Junius, I mean Biden.